Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › vildagliptin

vildagliptin

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of vildagliptin

9 trials tracked of vildagliptin: 8 in phase 3 or 4 and 2 with published results. The most-cited published study has 352 citations.

9Trials tracked
8Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 6 Phase 3 2 Phase 1 1
  1. Phase 4 VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus Completed · 352 cited
  2. Phase 3 Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes Completed · 53 cited
  3. Phase 4 Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients Completed
  4. Phase 4 Vildagliptin Versus Dapagliflozin on Glucagon Completed
  5. Phase 4 Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function Completed
  6. Phase 4 Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 Diabetes Completed
Show 3 more trials
  1. Phase 4 DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes Completed
  2. Phase 3 Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin Completed
  3. Phase 1 Evaluation of Continuous Glucose Monitoring in Participants With Type 2 Diabetes Mellitus (MK-0000-258 AM2) Completed

Showing the 9 most-cited and recently-updated of 9 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Network meta-analysis compares glucose-lowering therapies for heart failure with reduced ejection fraction and type 2 diabetes
Cardiology Meta-analysis
Network meta-analysis compares glucose-lowering therapies for heart failure with reduced ejection fraction and type 2 diabetes Sotagliflozin Cuts Heart Failure Risk By Half In High-Risk Patients
This systematic review and network meta-analysis synthesized evidence on three glucose-lowering therapies for patients with coexisting heart…
New drugs for diabetes could also save lives in people with heart failure and lower the need for hospital visits.
Frontiers May 8, 2026
Vildagliptin reduces specific TG species in T2D; GLP-1 blockade increases total TGs
Nutrition & Obesity Medicine RCT
Vildagliptin reduces specific TG species in T2D; GLP-1 blockade increases total TGs How does a diabetes drug affect blood fats after eating? A small study finds clues
A randomized controlled trial in 15 diet/metformin-managed T2D patients found vildagliptin reduced plasma TG(54:4) and TG(54:5) concentratio…
A diabetes drug called vildagliptin lowers specific blood fats after meals, but blocking the body's natural response to it causes total fat …
Diab Care Apr 3, 2026